Inhibikase Therapeutics Inc (NASDAQ: IKT) started the day on Thursday, with a price decrease of -4.04% at $1.90, before settling in for the price of $1.98 at the close. Taking a more long-term approach, IKT posted a 52-week range of $1.12-$4.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 44.23% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 18.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 57.33%. This publicly-traded company’s shares outstanding now amounts to $69.36 million, simultaneously with a float of $45.53 million. The organization now has a market capitalization sitting at $141.25 million. At the time of writing, stock’s 50-day Moving Average stood at $2.2537, while the 200-day Moving Average is $2.0991.
Inhibikase Therapeutics Inc (IKT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Inhibikase Therapeutics Inc’s current insider ownership accounts for 38.76%, in contrast to 52.65% institutional ownership. According to the most recent insider trade that took place on Oct 21 ’24, this organization’s Director bought 1,460,000 shares at the rate of 1.37, making the entire transaction reach 2,000,200 in total value, affecting insider ownership by 1,460,000. Preceding that transaction, on Oct 21 ’24, Company’s Director bought 145,000 for 1.37, making the whole transaction’s value amount to 198,650. This particular insider is now the holder of 145,000 in total.
Inhibikase Therapeutics Inc (IKT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Inhibikase Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 57.33% and is forecasted to reach -0.69 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 22.02% through the next 5 years, which can be compared against the 18.99% growth it accomplished over the previous five years trading on the market.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Trading Performance Indicators
Let’s observe the current performance indicators for Inhibikase Therapeutics Inc (IKT). It’s Quick Ratio in the last reported quarter now stands at 26.37. The Stock has managed to achieve an average true range (ATR) of 0.21.
In the same vein, IKT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.22, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.69 at the market close of one year from today.
Technical Analysis of Inhibikase Therapeutics Inc (IKT)
If we take a close look at the recent performances of Inhibikase Therapeutics Inc (NASDAQ: IKT), its last 5-days Average volume was 0.14 million that shows plunge from its year to date volume of 0.17 million. During the previous 9 days, stock’s Stochastic %D was recorded 56.86% While, its Average True Range was 0.2084.
Raw Stochastic average of Inhibikase Therapeutics Inc (IKT) in the period of the previous 100 days is set at 13.53%, which indicates a major fall in contrast to 45.57% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 105.65% that was lower than 116.16% volatility it exhibited in the past 100-days period.
